325. 遺伝性自己炎症疾患 Hereditary autoinflammatory syndrome Clinical trials / Disease details


臨床試験数 : 5 薬物数 : 11 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03304717
(ClinicalTrials.gov)
December 20234/8/2017Reverse Transcriptase Inhibitors in Aicardi Goutières SyndromeReverse Transcriptase Inhibitors in Aicardi Goutières SyndromeAicardi Goutières SyndromeDrug: Tenofovir (TDF) and Emtricitabine (FTC);Other: PlaceboChildren's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Human Genome Research Institute (NHGRI);Gilead Sciences;Emerson Resources;National Institutes of Health (NIH)Not yet recruiting2 Years18 YearsAll34Phase 1/Phase 2United States
2NCT05613868
(ClinicalTrials.gov)
March 20237/11/2022TPN-101 in Aicardi-Goutières Syndrome (AGS)A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)Aicardi-Goutières Syndrome (AGS)Drug: TPN-101Transposon Therapeutics, Inc.NULLNot yet recruiting12 MonthsN/AAll16Phase 2France;Italy;United Kingdom
3NCT02363452
(ClinicalTrials.gov)
September 10, 201515/1/2015Reverse Transcriptase Inhibitors in AGSA Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)Aicardi-Goutières Syndrome (AGS)Drug: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, AbacavirAssistance Publique - Hôpitaux de ParisNULLCompleted1 Month17 YearsAll11Phase 2France
4NCT01724580
(ClinicalTrials.gov)
October 20125/11/2012Compassionate Use Protocol for the Treatment of Autoinflammatory SyndromesCompassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile DermatomyositisChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);Juvenile Dermatomyositis (JDM);Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI);Aicardi-Goutières Syndrome (AGS)Drug: BaricitinibEli Lilly and CompanyNULLNo longer available6 MonthsN/AAllUnited States;United Kingdom
5EUCTR2015-003424-31-GB
(EUCTR)
07/12/2015Treatment of autoinflammatory diseasesTreatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis - JAGA CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: Baricitinib
Product Code: LY3009104
INN or Proposed INN: Baricitinib
Other descriptive name: BARICITINIB
INN or Proposed INN: Baricitinib
Other descriptive name: BARICITINIB
INN or Proposed INN: baricitinib
Other descriptive name: BARICITINIB
Eli Lilly and CompanyNULLNAFemale: yes
Male: yes
60Phase 2France;United States;United Kingdom